KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Shares Outstanding (Diluted Average) (2016 - 2026)

Pacira BioSciences has reported Shares Outstanding (Diluted Average) over the past 17 years, most recently at $40.9 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Diluted Average) fell 12.07% year-over-year to $40.9 million; the TTM value through Mar 2026 reached $40.9 million, down 12.07%, while the annual FY2025 figure was $45.0 million, 2.6% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q1 2026 was $40.9 million at Pacira BioSciences, down from $45.0 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $52.5 million in Q2 2022 and troughed at $40.9 million in Q1 2026.
  • A 5-year average of $47.4 million and a median of $46.3 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 15.1% in 2022 and later decreased 12.07% in 2026.
  • Year by year, Shares Outstanding (Diluted Average) stood at $46.5 million in 2022, then rose by 11.69% to $52.0 million in 2023, then dropped by 11.03% to $46.2 million in 2024, then dropped by 2.6% to $45.0 million in 2025, then fell by 9.17% to $40.9 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for PCRX at $40.9 million in Q1 2026, $45.0 million in Q4 2025, and $44.5 million in Q3 2025.